These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38403867)

  • 1. Consensus statement on the management of hyperkalaemia-An Asia-Pacific perspective.
    Yap DYH; Ma RCW; Wong ECK; Tsui MSH; Yu EYT; Yu V; Szeto CC; Pang WF; Tse HF; Siu DCW; Tan KCB; Chen WWC; Li CL; Chen W; Chan TM
    Nephrology (Carlton); 2024 Jun; 29(6):311-324. PubMed ID: 38403867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approaches to management of hyperkalaemia in kidney transplantation.
    Rizk J; Quan D; Gabardi S; Rizk Y; Kalantar-Zadeh K
    Curr Opin Nephrol Hypertens; 2021 Jan; 30(1):27-37. PubMed ID: 33027094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease.
    Rossignol P; Silva-Cardoso J; Kosiborod MN; Brandenburg V; Cleland JG; Hadimeri H; Hullin R; Makela S; Mörtl D; Paoletti E; Pollock C; Vogt L; Jadoul M; Butler J
    Pharmacol Res; 2022 Aug; 182():106277. PubMed ID: 35662631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of sodium zirconium cyclosilicate: a new treatment option for hyperkalaemia in China.
    Lu Y; Liu BC; Liu H
    Expert Opin Pharmacother; 2023 Feb; 24(3):301-308. PubMed ID: 36617700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical guidance for the use of potassium binders in the management of hyperkalaemia in patients with heart failure and/or chronic kidney disease.
    Campbell P; McKeveney P; Donegan K; Ataliotis C; Patton C; Mullan R
    Br J Hosp Med (Lond); 2021 Apr; 82(4):1-11. PubMed ID: 33914625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New potassium binders effective: treatment of hyperkalaemia secondary to RAAS inhibitors].
    Hoorn EJ
    Ned Tijdschr Geneeskd; 2015; 159():A8801. PubMed ID: 25761299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia.
    Hoy SM
    Drugs; 2018 Oct; 78(15):1605-1613. PubMed ID: 30306338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
    Palmer BF
    Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in treatment of hyperkalemia in chronic kidney disease.
    Sarafidis PA; Georgianos PI; Bakris GL
    Expert Opin Pharmacother; 2015; 16(14):2205-15. PubMed ID: 26330193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
    Rosano GMC; Tamargo J; Kjeldsen KP; Lainscak M; Agewall S; Anker SD; Ceconi C; Coats AJS; Drexel H; Filippatos G; Kaski JC; Lund L; Niessner A; Ponikowski P; Savarese G; Schmidt TA; Seferovic P; Wassmann S; Walther T; Lewis BS
    Eur Heart J Cardiovasc Pharmacother; 2018 Jul; 4(3):180-188. PubMed ID: 29726985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
    Santoro A; Mandreoli M
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland.
    Ward T; Brown T; Lewis RD; Kliess MK; de Arellano AR; Quinn CM
    Pharmacoecon Open; 2022 Sep; 6(5):757-771. PubMed ID: 35925491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
    Schaefer JA; Gales MA
    Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of potassium-binder patiromer for up-titration of renin-angiotensin-aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report.
    Jiménez-Marrero S; Enjuanes C; Yun S; Comín-Colet J
    Eur Heart J Case Rep; 2020 Aug; 4(4):1-4. PubMed ID: 32974448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In pursuit of balance: renin-angiotensin-aldosterone system inhibitors and hyperkalaemia treatment.
    Sciatti E; D'Elia E; Balestrieri G; D'Isa S; Iacovoni A; Senni M
    Eur Heart J Suppl; 2023 May; 25(Suppl C):C301-C305. PubMed ID: 37125304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience of a Bespoke Hyperkalaemia Clinic to Facilitate Prescribing of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction.
    Ali I; Green D; Kalra P; Kalra PA
    Cardiorenal Med; 2022; 12(5-6):196-204. PubMed ID: 36044877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum.
    Burton JO; Coats AJS; Kovesdy CP; Palmer BF; Piña IL; Rosano G; Sood MM; Zieroth S
    Eur J Heart Fail; 2022 Sep; 24(9):1467-1477. PubMed ID: 35791065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperkalaemia in Heart Failure-Pathophysiology, Implications and Therapeutic Perspectives.
    Llubani R; Vukadinović D; Werner C; Marx N; Zewinger S; Böhm M
    Curr Heart Fail Rep; 2018 Dec; 15(6):390-397. PubMed ID: 30421355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
    Takkar C; Nassar T; Qunibi W
    Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.